---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-063967"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T15:39:39.104532+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Heron settles patent litigation with Mylan, grants generic license for CINVANTI/APONVIE starting June 2032

## Summary
- Settlement resolves patent litigations in U.S. District Court for Delaware initiated in Sep 2023 and Jan 2024.
- Heron grants Mylan a license to market generic CINVANTI and APONVIE beginning June 1, 2032 (or earlier under certain circumstances).
- Patent protection for CINVANTI and APONVIE extends to 2035; license starts ~3 years before expiration.
- Parties will file stipulation to dismiss pending litigations.

## SEC filing metadata
- accession: 0000950170-25-063967
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017025063967/0000950170-25-063967-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017025063967/hrtx-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-063967
- JSON: https://secwatch.observer/filing/0000950170-25-063967.json
- Plain text: https://secwatch.observer/filing/0000950170-25-063967.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.